Key terms
About CRMD
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRMD news
Apr 15
8:39am ET
CorMedix announces U.S. inpatient availability of DefenCath
Apr 11
8:33am ET
CorMedix announces abstracts at upcoming SHEA conference
Apr 09
7:35am ET
Truist Financial Remains a Buy on Cormedix (CRMD)
Apr 09
6:05am ET
Understanding Analyst Recommendation Reports: A Comprehensive Summary
Apr 09
12:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
Apr 08
8:45am ET
CorMedix enters commercial agreement with ARC Dialysis
Mar 13
9:02am ET
CorMedix price target lowered to $9 from $10 at RBC Capital
Mar 13
7:35am ET
Truist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)
Mar 13
6:41am ET
Analysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)
Mar 13
6:40am ET
RBC Capital Remains a Buy on Cormedix (CRMD)
Mar 13
2:00am ET
Cormedix Inc.’s DefenCath Success Hinges on Two Major Dialysis Providers: A High-Stakes Gamble in Outpatient Market Adoption
Mar 12
3:35pm ET
Buy Rating on Cormedix Amidst DefenCath Launch and Strong Financial Positioning
Mar 12
12:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), PROCEPT BioRobotics (PRCT)
Mar 12
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 12, 2024
Mar 12
7:34am ET
CorMedix expects cash to fund operations for at least 12 months
Mar 12
7:34am ET
CorMedix reports Q4 EPS (26c), consensus (20c)
Jan 30
3:35pm ET
Buy Rating Affirmed on Cormedix Following DefenCath Reimbursement Approval and Strong Launch Outlook
Jan 30
12:45pm ET
Buy Rating Affirmed: Cormedix’s DefenCath Poised for Success with Positive Reimbursement Outlook and Strategic Launch Plan
Jan 30
8:33am ET
CorMedix announces commercial, reimbursement updates
No recent press releases are available for CRMD
CRMD Financials
Key terms
Ad Feedback
CRMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
